Holen Sie sich die Stockscreener-App
37.63
0.51%
0.19
Schlusskurs vom Vortag:
$37.44
Offen:
$37.09
24-Stunden-Volumen:
521.58K
Relative Volume:
0.38
Marktkapitalisierung:
$2.99B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-237.22M
KGV:
-9.955
EPS:
-3.78
Netto-Cashflow:
$-212.64M
1W Leistung:
+8.07%
1M Leistung:
-16.04%
6M Leistung:
+22.10%
1J Leistung:
+74.21%
1-Tages-Spanne:
$36.67
$37.85
1-Wochen-Bereich:
$34.18
$39.13
52-Wochen-Spanne:
$17.86
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Vergleichen Sie AKRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
37.63 | 2.99B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
University of Wisconsin Foundation Has $11.42 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Catriona Yale Sells 9,073 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
8,336 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Optimize Financial Inc - MarketBeat
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
F M Investments LLC Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
JPMorgan Chase & Co. Acquires 40,161 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics chief development officer sells $343,962 in shares By Investing.com - Investing.com India
Akero Therapeutics chief development officer sells $343,962 in shares - Investing.com
Geode Capital Management LLC Reduces Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Sei Investments Co. Invests $303,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - markets.businessinsider.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by ExodusPoint Capital Management LP - MarketBeat
Vanguard Group Inc. Has $103.06 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect - markets.businessinsider.com
JPMorgan Chase & Co. Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Schroder Investment Management Group Sells 158,817 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero therapeutics CEO Andrew Cheng sells $1.06 million in stock - Investing.com
Sei Investments Co. Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Springhill Fund Asset Management HK Co Ltd Takes $4.21 Million Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero therapeutics chief scientific officer sells $224,261 in stock By Investing.com - Investing.com South Africa
11,000 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by KLP Kapitalforvaltning AS - MarketBeat
Akero therapeutics chief scientific officer sells $224,261 in stock - Investing.com
American Century Companies Inc. Has $3.13 Million Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Vanguard Group Inc. Has $103.06 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Alliancebernstein L.P. Reduces Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) PT at $76.29 - Defense World
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - TradingView
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - GlobeNewswire Inc.
KLP Kapitalforvaltning AS Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
American Century Companies Inc. Acquires 39,932 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 7.3%Here's Why - MarketBeat
Wellington Management Group LLP Decreases Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock (NASDAQ:AKRO) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Corebridge Financial Inc. Decreases Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
NEOS Investment Management LLC Sells 10,929 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Liver Fibrosis Market Set to Grow Substantially Through 2034, - openPR.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect - markets.businessinsider.com
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):